ULTRAGENYX PHARMACEUTICAL INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $41.75 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $41.75, a 21.09% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $52.91, a 17.45% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $45.05, a 30.56% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $64.88, a 49.56% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $41.75 10-K · filed 2026-02-18 |
| 2024-12-31 | $52.91 10-K · filed 2025-02-19 |
| 2023-12-31 | $45.05 10-K · filed 2024-02-21 |
| 2022-12-31 | $64.88 10-K · filed 2023-02-17 |
| 2021-12-31 | $128.63 10-K · filed 2022-02-15 |
| 2020-12-31 | $62.51 10-K · filed 2022-02-15 |
| 2019-12-31 | $63.03 10-K · filed 2022-02-15 |
| 2018-12-31 | $55.54 10-K · filed 2021-02-12 |
| 2017-12-31 | $71.99 10-K · filed 2020-02-14 |
| 2016-12-31 | $67.00 10-K · filed 2019-02-20 |
| 2015-12-31 | $90.60 10-K · filed 2018-02-21 |
| 2014-12-31 | $41.12 10-K · filed 2017-02-17 |
| 2013-12-31 | $5.80 10-K · filed 2016-02-26 |
| 2012-12-31 | $0.81 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |